1. Search Result
Search Result
Results for "

Gastric acid

" in MedChemExpress (MCE) Product Catalog:

874

Inhibitors & Agonists

1

Screening Libraries

10

Fluorescent Dyes

28

Biochemical Assay Reagents

79

Peptides

3

MCE Kits

52

Inhibitory Antibodies

121

Natural
Products

11

Recombinant Proteins

69

Isotope-Labeled Compounds

6

Antibodies

4

Click Chemistry

3

Oligonucleotides

2

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0276
    GIP, human
    2 Publications Verification

    Gastric Inhibitory Peptide (GIP), human

    Insulin Receptor Metabolic Disease
    GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .
    GIP, human
  • HY-B0218
    Orlistat
    30+ Cited Publications

    Tetrahydrolipstatin; Ro-18-0647

    Fatty Acid Synthase (FASN) Apoptosis Metabolic Disease Cancer
    Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity . Anti-atherosclerotic effect .
    Orlistat
  • HY-P1635
    Pepsin
    3 Publications Verification

    EC 3.4.23.1

    Endogenous Metabolite Endocrinology
    Pepsin is the major pig and human gastric proteases, it is a pepsin-like minor gastric proteolytic enzymes. Pepsin contributes to proteolysis of food proteins in the vertebrate stomach .
    Pepsin
  • HY-B2196
    Gastric mucin
    3 Publications Verification

    Antibiotic Bacterial Infection Metabolic Disease
    Gastric mucin is a glycoprotein with natural antibiotic function. Gastric mucin against Helicobacter pylori infection. Gastric mucin effectively scavenges hydroxyl radical. Gastric mucin play a major role in the protection of the gastrointestinal tract from acid, proteases, pathogenic microorganisms, and mechanical trauma .
    Gastric mucin
  • HY-15295
    Vonoprazan Fumarate
    5+ Cited Publications

    TAK-438

    Proton Pump Metabolic Disease Cancer
    Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .
    Vonoprazan Fumarate
  • HY-17623
    Tegoprazan
    2 Publications Verification

    CJ-12420; RQ-00000004

    Proton Pump Potassium Channel Na+/K+ ATPase Inflammation/Immunology
    Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H +/K +-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H +/K +-ATPase with IC50 values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
    Tegoprazan
  • HY-100007
    Vonoprazan
    5+ Cited Publications

    TAK-438 free base

    Proton Pump Bacterial Endocrinology Cancer
    Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .
    Vonoprazan
  • HY-A0261
    Pentagastrin
    1 Publications Verification

    ICI-50123

    Cholecystokinin Receptor Metabolic Disease Cancer
    Pentagastrin (ICI-50123) is a potent, selective Cholecystokinin B (CCKB) receptor agonist with an EC50 value of 11 nM. Pentagastrin enhances gastric mucosal defense mechanisms against acid and protects the gastric mucosa from experimental injury .
    Pentagastrin
  • HY-P0276A
    GIP, human TFA
    2 Publications Verification

    Gastric Inhibitory Peptide (GIP), human TFA

    Insulin Receptor Metabolic Disease
    GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .
    GIP, human TFA
  • HY-P10735

    Gastric inhibitory polypeptide(mouse); GIP(1-42) (mouse)

    Lipase Apoptosis Metabolic Disease
    GIP (Gastric inhibitory polypeptide) (mouse) is a gastrointestinal hormone that is secreted by the intestinal K cells, and also expressed in and secreted from pancreatic islets. GIP (mouse) promotes insulin secretion from pancreatic β cells via the G-protein-coupled GIP receptor (GIPR). GIP (mouse) promotes pancreatic β cell proliferation and inhibits apoptosis. GIP (mouse) also exerts direct lipogenic effects on adipose tissue .
    GIP (mouse)
  • HY-17421

    TU-199

    Proton Pump Infection Inflammation/Immunology
    Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H +/K +-ATPase activity with an IC50 of 6.2 μM. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV .
    Tenatoprazole
  • HY-W116335A

    Environmental Pollutants Biochemical Assay Reagents Inflammation/Immunology
    Dried aluminum hydroxide gel, United States Pharmacopeia (USP) Reference Standard is a commonly used antacid with remarkable compound adhesion and release activity. Dried aluminum hydroxide gel, United States Pharmacopeia (USP) Reference Standard can effectively neutralize gastric acid and relieve stomach discomfort. Dried aluminum hydroxide gel, United States Pharmacopeia (USP) Reference Standard is also often used as an adjuvant in vaccines to enhance immune responses. Dried aluminum hydroxide gel, United States Pharmacopeia (USP) Reference Standard can improve the stability and bioavailability of compounds in preparations .
    Dried aluminum hydroxide gel,United States Pharmacopeia (USP) Reference Standard
  • HY-14850
    Sograzepide
    1 Publications Verification

    Netazepide; YF 476; YM-220

    Cholecystokinin Receptor Metabolic Disease Endocrinology
    Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent, highly selective and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC50 of 502 nM . Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with Ki values of 0.068, 0.62 and 0.19 nM, respectively .
    Sograzepide
  • HY-N7067
    Revaprazan hydrochloride
    2 Publications Verification

    Proton Pump Bacterial COX NF-κB ERK Akt Infection Inflammation/Immunology
    Revaprazan hydrochloride is reversible proton pump inhibitor. Revaprazan hydrochloride can inhibit gastric acid secretion and protect gastric mucosa. Revaprazan hydrochloride can inhibit IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori-induced COX-2 expression. Revaprazan hydrochloride can be used for the researches of infection and inflammmation, such as H. pylori-infected gastric inflammation and gastric ulcer .
    Revaprazan hydrochloride
  • HY-139557

    JP-1366

    Proton Pump Inflammation/Immunology
    Zastaprazan (JP-1366) is a proton pump inhibitor and a potent potassium-competitive acid blocker. Zastaprazan can be used in the research of gastrointestinal inflammatory diseases or gastric acid-related diseases such as gastroesophageal reflux disease .
    Zastaprazan
  • HY-139557A

    JP-1366 citrate

    Proton Pump Inflammation/Immunology
    Zastaprazan (JP-1366) citrate is a Proton pump inhibitor and potent potassium-competitive acid blocker. Zastaprazan citrate can be used in the research of gastrointestinal inflammatory diseases or gastric acid-related diseases such as gastroesophageal reflux disease .
    Zastaprazan citrate
  • HY-101664

    IY-81149

    Proton Pump TOPK Inflammation/Immunology Cancer
    Ilaprazole (IY-81149) is an orally active proton pump inhibitor. Ilaprazole irreversibly inhibits H +/K +-ATPase in a dose-dependent manner with an IC50 of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Ilaprazole is used for the research of gastric ulcers. Ilaprazole is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .
    Ilaprazole
  • HY-B2184
    Sofalcone
    2 Publications Verification

    Autophagy Bacterial Infection Inflammation/Immunology
    Sofalcone, a gastric antiulcer agent, is known to induce the expression of Heme oxygenase-1 (HO-1) in gastric epithelium.
    Sofalcone
  • HY-121467

    Z-338 free base; YM443 free base

    Cholinesterase (ChE) Metabolic Disease Inflammation/Immunology
    Acotiamide is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC50 of 1.79 μM. Acotiamide can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .
    Acotiamide
  • HY-P3579

    GIP (1-42), porcine

    Insulin Receptor Metabolic Disease
    Gastric Inhibitory Peptide (GIP (1-42)), porcine is a porcine glucose-dependent insulinotropic polypeptide and inhibitor of pentagastrin-stimulated gastric acid secretion. Gastric Inhibitory Peptide, porcine stimulates endogenous somatostatin release. Gastric Inhibitory Peptide, porcine acts in a dose- and time-dependent manner in conscious, chronic gastric fistula-equipped rats .
    Gastric Inhibitory Peptide, porcine
  • HY-B1478

    Histamine Receptor NO Synthase Endocrinology
    Dimaprit dihydrochloride is a selective histamine H2 receptor agonist, it also inhibits nNOS with an IC50 of 49 μM. Dimaprit dihydrochloride can stimulate gastric acid secretion .
    Dimaprit dihydrochloride
  • HY-B2145

    IY-81149 sodium

    Proton Pump TOPK Inflammation/Immunology Cancer
    Ilaprazole (IY-81149) sodium is an orally active proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H +/K +-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .
    Ilaprazole sodium
  • HY-P0253

    Neurotensin Receptor Metabolic Disease
    Xenopsin, a neurotensin-like octapeptide from Xenopus laevis skin . Xenopsin is an inhibitor of Tetragastrin stimulated gastric acid secretion .
    Xenopsin
  • HY-B1475

    Octatropine bromide

    mAChR Neurological Disease Metabolic Disease
    Anisotropine (Octatropine) bromide is an orally active anticholinergic muscarinic antagonist. Anisotropine bromide can inhibit gastric acid secretion and is used as an adjunct to peptic ulcers .
    Anisotropine bromide
  • HY-B1610I
    Sodium citrate dihydrate, for molecular biology
    Maximum Cited Publications
    11 Publications Verification

    Trisodium citrate dihydrate, for molecular biology

    Biochemical Assay Reagents Others
    Sodium citrate dihydrate, for molecular biology is an antacid used in studies to neutralize gastric acid. Sodium citrate dehydrate is often used to prepare biological buffers and can be used in molecular biology research .
    Sodium citrate dihydrate, for molecular biology
  • HY-103355
    YM022
    2 Publications Verification

    CCR Metabolic Disease
    YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively . YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo .
    YM022
  • HY-165131

    Delta-7-avenasterol

    Prostaglandin Receptor COX Inflammation/Immunology
    Δ7-Avenasterol (Delta-7-avenasterol) is a phytosterol that binds to prostaglandin E2 receptor (prostaglandin E2 receptor) and cyclooxygenase-2 (COX-2). Δ7-Avenasterol is applicable to research related to gastric ulcer, anti-inflammation and antioxidation .
    Δ7-Avenasterol
  • HY-145453

    Interleukin Related Inflammation/Immunology
    Propacetamol is an orally active prodrug of Acetaminophen (HY-66005), which exerts antipyretic and analgesic effects after metabolism. Propacetamol reduces Aspirin (ASA) (HY-14654)-induced elevation of malondialdehyde (MDA) in gastric mucosa and plasma, regulates the levels of gastric mucosal glutathione (GSH and GSSG) to maintain cellular antioxidant defense, and increases gastric mucosal uric acid (UA) levels. Propacetamol exerts a dose-dependent protective effect against ASA-induced gastric mucosal damage in rats. Propacetamol can be used for the study of gastric mucosal injury by interfering with oxidative stress .
    Propacetamol
  • HY-P3580A

    Human N-acetyl GIP TFA

    Insulin Receptor Metabolic Disease Endocrinology
    Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity .
    Acetyl Gastric Inhibitory Peptide (human) TFA
  • HY-P2416

    Rat Gastrin-17

    Cholecystokinin Receptor Endocrinology
    Gastrin I, rat (Rat Gastrin-17) is a peptide hormone, can stimulate gastric acid secretion potently .
    Gastrin I, rat
  • HY-B1789A

    mAChR Neurological Disease
    Telenzepine dihydrochloride is a selective and orally active muscarinic M1 receptor antagonist with a Ki of 0.94 nM. Telenzepine dihydrochloride inhibits gastric acid secretion and has antiulcer effects .
    Telenzepine dihydrochloride
  • HY-109546

    Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole (H 16868) magnesium is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole magnesium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole magnesium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole magnesium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole magnesium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole magnesium aslo has neuroprotective and antibacterial effects .
    Omeprazole magnesium
  • HY-145578

    X842

    Drug Intermediate Proton Pump Metabolic Disease
    Linaprazan glurate (X842) is an orally atcive prodrug of Linaprazan (HY-100412) with a potent and prolonged inhibitory effect on gastric acid secretion. Linaprazan glurate is rapidly transformed by enzymatic cleavage into its active metabolite, linaprazan. Linaprazan glurate is a potassium-competitive acid blocker. Linaprazan glurate selectively inhibites acid formation from gastric H⁺/K⁺-ATPase in a potassium-dependent manner (IC50 = 436.2 nM). Linaprazan glurate can be used for the studies of erosive esophagitis (EE) .
    Linaprazan glurate
  • HY-103281

    Bombesin Receptor Metabolic Disease
    Litorin, an amphibian bombesin peptide derivative, is an bombesin receptor agonist. Litorin stimulates the contraction of smooth muscle, stimulates gastrin, gastric acid, and pancreatic secretion, and suppresses the nutriment in vivo .
    Litorin
  • HY-100007A
    Vonoprazan hydrochloride
    5+ Cited Publications

    TAK-438 hydrochloride

    Proton Pump Bacterial Infection Endocrinology Cancer
    Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .
    Vonoprazan hydrochloride
  • HY-P1139

    PCFWKTCK

    GHSR Metabolic Disease
    Cortistatin-8 (CST-8; PCFWKTCK), a neuropeptide, is a GHS-R1a antagonist by counteracting the response of ghrelin on gastric acid secretion. Cortistatin-8 can modulate GH release from somatotroph cells. Cortistatin-8 is a synthetic CST-analogue devoid of any binding affinity to SST-R but capable to bind the GHS-R1a. Cortistatin-8 can exert antagonistic effects on ghrelin actions either in vitro or in vivo in animals .
    Cortistatin-8
  • HY-P3584A

    (Pro3) Gastric Inhibitory Peptide, human TFA

    Insulin Receptor Metabolic Disease
    (Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with Ki/ Kd value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes .
    (Pro3) GIP, human TFA
  • HY-121851

    SB 641257

    Proton Pump Bacterial COX NF-κB ERK Akt Infection Inflammation/Immunology
    Revaprazan (SB 641257) is reversible proton pump inhibitor. Revaprazan can inhibit gastric acid secretion and protect gastric mucosa. Revaprazan can inhibit IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori-induced COX-2 expression. Revaprazan can be used for the researches of infection and inflammmation, such as H. pylori-infected gastric inflammation and gastric ulcer .
    Revaprazan
  • HY-W002039

    DL-β-Phenylalanine

    Biochemical Assay Reagents Endocrinology
    3-Amino-3-phenylpropionic acid (DL-β-Phenylalanine) is a structural GABA analogue. 3-Amino-3-phenylpropionic acid inhibits baclofen (HY-B0007) induced gastric acid secretion .
    3-Amino-3-phenylpropionic acid
  • HY-177506

    Cholecystokinin Receptor Metabolic Disease
    FE100726 (Compound 39) is a Cholecystokinin 2 (CCK2) receptor agonist. FE100726 has a superior binding capacity on CCK2 receptor. FE100726 can induce gastric acid secretion in anaesthetized rat models. FE100726 can be used for diabetes research .
    FE100726
  • HY-B1557
    Betazole
    1 Publications Verification

    Ametazole

    Histamine Receptor Metabolic Disease
    Betazole (Ametazole), a pyrazole analogue of histamine, is an orally active histamine H2 receptor agonist. Betazole induces gastric acid secretion and causes an immediate and significant increase in common bile duct pressure. Betazole is used as a diagnostic agent known as histalog for investigating gastric acid secretory capacity .
    Betazole
  • HY-N7031

    (±)​-Peganine

    Proton Pump Inflammation/Immunology
    (±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H +-K +-ATPase activity in vitro with an IC50 of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and cytoprotective effect .
    (±)​-​Vasicine
  • HY-121467A

    Z-338; YM443

    Cholinesterase (ChE) Others Metabolic Disease Inflammation/Immunology
    Acotiamide hydrochloride is an orally active, selective and reversible acetylcholinesterase (AChE) inhibitor, with an IC50 of 1.79 μM. Acotiamide hydrochloride can enhance gastric contractility and accelerate delayed gastric emptying. Acotiamide hydrochloride has the potential for the research of functional dyspepsia involving gastric motility dysfunction and intestinal inflammatory .
    Acotiamide hydrochloride
  • HY-17623R

    CJ-12420 (Standard); RQ-00000004 (Standard)

    Reference Standards Proton Pump Metabolic Disease
    Tegoprazan (Standard) is the analytical standard of Tegoprazan. This product is intended for research and analytical applications. Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H +/K +-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro .
    Tegoprazan (Standard)
  • HY-B1557A

    Ametazole dihydrochloride

    Histamine Receptor Metabolic Disease
    Betazole (Ametazole) dihydrochloride, a pyrazole analogue of histamine, is an orally active H2 receptor agonist. Betazole dihydrochloride induces gastric acid secretion, and causes an immediate and significant increase in common bile duct pressure. Betazole dihydrochloride has been used as a diagnostic agent known as histalog, for investigating gastric acid secretory capacity .
    Betazole dihydrochloride
  • HY-17623S

    CJ-12420-d6; RQ-00000004-d6

    Proton Pump Na+/K+ ATPase Metabolic Disease
    Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
    Tegoprazan-d6
  • HY-P3584

    (Pro3) Gastric Inhibitory Peptide, human

    Insulin Receptor Metabolic Disease
    (Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human has high binding affinity for human GIPR with Ki/ Kd values of 0.90 nM. (Pro3) GIP, human can be used for the research of obesity-related diabetes .
    (Pro3) GIP, human
  • HY-15295R

    TAK-438 (Standard)

    Proton Pump Reference Standards Metabolic Disease Cancer
    Vonoprazan (Fumarate) (Standard) is the analytical standard of Vonoprazan (Fumarate). This product is intended for research and analytical applications. Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .
    Vonoprazan Fumarate (Standard)
  • HY-P3580

    Human N-acetyl GIP

    Insulin Receptor Metabolic Disease Endocrinology
    Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity .
    Acetyl Gastric Inhibitory Peptide (human)
  • HY-117216

    Neurokinin Receptor Neurological Disease
    L-703606 is a potent, selective antagonist of NK1 receptor. L-703606 can be used for study of gastric acid secretion .
    L-703606

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: